400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / PI3K/Akt/mTOR / Akt / 哌立福新
CAS No.: 157716-52-4
Synonyms: KRX-0401;NSC 639966;D21266
Perifosine is an Akt inhibitor with IC50 of 4.7 μM, targets pleckstrin homology domain of Akt.
生物活性
靶点 | Akt IC50:4.7μM |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01555281 | Multiple Myeloma | Phase 1 Phase 2 | Active, not recruiting | December 2019 | Italy ... more >> Istituto Europeo di Oncologia IEO Milano, Italy, 20141 University of Torino Torino, Italy, 10127 Switzerland Kantonsspital Aarau Aarau, Switzerland, 5001 Kantonsspital Baden Baden, Switzerland, 5404 Istituto Oncologico Svizzera Italiana IOSI Bellinzona, Switzerland, 6500 Inselspital Bern Bern, Switzerland, 3010 Kantonsspital Graubünden Chur, Switzerland, 7000 Kantonsspital Olten Olten, Switzerland, 4600 Kantonsspital St. Gallen St. Gallen, Switzerland, 9007 Regionalspital Thun, Switzerland, 3600 UniversitätsSpital Zürich Zürich, Switzerland, 8091 Collapse << |
NCT00055380 | Cancer | Phase 1 | Completed | - | United States, Maryland ... more >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Collapse << |
NCT00053794 | Endometrial Cancer ... more >> Sarcoma Collapse << | Phase 2 | Completed | - | Canada, Alberta ... more >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Island Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Canada, Quebec Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 Collapse << |
实验方案
技术信息
CAS号 | 157716-52-4 | 储存条件 |
|
|||||||
分子式 | C25H52NO4P | 运输 | 蓝冰 | |||||||
分子量 | 461.66 | 别名 | KRX-0401;NSC 639966;D21266;NKA17;哌立福新 | |||||||
溶解度 |
|
动物实验配方 |
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
769-P | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~5-10 μM | 21644050 |
769-P | 0-20 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 21644050 |
786-0 | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~5 μM | 21644050 |
786-O | 0-20 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 21644050 |
A2780 | 1-30 μM | Cell Viability Assay | 48 h | decreases cell viability in a dose dependent manner | 25519148 |
A2780 | 5 μM | Cytotoxicity Assay | 48 h | enhances paclitaxel induced ovarian cancer cell death | 21775054 |
A2780 | 0-20 μM | Growth Inhibition Assay | 48/72 h | IC50 = 3 μm | 20405296 |
A2780cis | 0-20 μM | Growth Inhibition Assay | 48/72 h | IC50 = 6 μm | 20405296 |
A2780CP | - | Growth Inhibition Assay | - | IC50=7.6 μM | 23877012 |
A2780S | - | Growth Inhibition Assay | - | IC50=14.5 μM | 23877012 |
A498 | 0-40 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 21644050 |
A498 | 0-20 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 21644050 |
A549 | 0.3-10 μM | Growth Inhibition Assay | 24/72 h | inhibits cell growth in both time and dose dependent manner | 25697899 |
A549 | 1/3 μM | Apoptosis Asssay | 48 h | induces apoptosis | 25697899 |
A549 | 3 μM | Function Assay | 8 h | blocks AKT activation | 25697899 |
A549 | 3 μM | Function Assay | 8 h | blocks mTORC1, and ERK-MAPK activation combined with MEK-162 | 25697899 |
AsPC-1 | 0-25 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 24519751 |
AsPC-1 | 0.5 μM | Function Assay | 24 h | inhibits Akt, S6K1, and Erk1/2 phosphorylation | 24519751 |
Bel-7402 | 5/10/20/40 μM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time and dose dependent manner | 20842425 |
Bel-7402 | 5/10/20 μM | Function Assay | 24 h | results in the accumulation of cell number in the G2/M phase | 20842425 |
Bel-7402 | 5/10/20 μM | Apoptosis Asssay | 24/48 h | induces apoptosis at the long-time exposure | 20842425 |
BJAB | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
BJAB | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
BON1 | 0-100 μM | Cell Viability Assay | 24/72 h | decreases cell viability in both dose and time dependent manner | 22499437 |
BON1 | 0-10 μM | Apoptosis Asssay | 24 h | induces apoptosis dose dependently | 22499437 |
BON1 | 7.5/10 μM | Function Assay | 8 h | decreases the expression of the anti-apoptotic proteins BCL2 and Bcl-XL | 22499437 |
CAKI-1 | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~10 μM | 21644050 |
CAKI-1 | 0-20 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 21644050 |
CaOV3 | 1/5/10 μM | Cell Viability Assay | 48 h | decreases cell viability in a dose dependent manner cotreated with paclitaxel | 21775054 |
CLBL-1 | 0.1–100 μM | Growth Inhibition Assay | 48 h | IC50=33.0 μM | 24881508 |
CWR22RV1 | 10 μM | Cell Viability Assay | 24 h | increases sensitivity of human CWR22RV1 cells to radiation | 21496273 |
CWR22RV1 | 10 μM | Apoptosis Asssay | 24 h | enhances radiation induced apoptosis | 21496273 |
CWR22RV1 | 5 μM | Function Assay | 24 h | reduced phosphorylation of Akt significantly | 21496273 |
Ema | 0.1–100 μM | Growth Inhibition Assay | 48 h | IC50=58.7 μM | 24881508 |
GL-1 | 0.1–100 μM | Growth Inhibition Assay | 48 h | IC50=9.91 μM | 24881508 |
GOT1 | 0-100 μM | Cell Viability Assay | 24/72 h | decreases cell viability in both dose and time dependent manner | 22499437 |
H460 | 0.3-10 μM | Growth Inhibition Assay | 24/72 h | inhibits cell growth in both time and dose dependent manner | 25697899 |
H460 | 1/3 μM | Apoptosis Asssay | 48 h | induces apoptosis | 25697899 |
H460 | 3 μM | Function Assay | 8 h | blocks AKT activation | 25697899 |
H460 | 3 μM | Function Assay | 8 h | blocks mTORC1, and ERK-MAPK activation combined with MEK-162 | 25697899 |
HAC2 | 1-30 μM | Cell Viability Assay | 72 h | decreases cell viability in a dose dependent manner | 25519148 |
HCC1806 | 0-10 μM | Growth Inhibition Assay | 48 h | EC50=2.84 ± 0.07 μM | 25293576 |
HepG2 | 20 μM | Function Assay | 24 h | produces an intense cytoplasmic vacuolization corresponding to a notable dilatation of the ER cisterns | 25934232 |
HepG2 | 20 μM | Function Assay | 6/24 h | increases the levels of LC3-II cotreated with CQ | 25934232 |
HepG2 | 20 μM | Function Assay | 6/24 h | decreases LC3-II degradation from 6 h | 25934232 |
HepG2 | 20/40 μM | Growth Inhibition Assay | 24/48 h | inhibits cell growth in both time and dose dependent manner | 25934232 |
HepG2 | 5/10/20/40 μM | Growth Inhibition Assay | 24/48/72 h | inhibits cell growth in both time and dose dependent manner | 20842425 |
HepG2 | 5/10/20 μM | Function Assay | 24 h | results in the accumulation of cell number in the G2/M phase | 20842425 |
HepG2 | 5/10/20 μM | Apoptosis Asssay | 24/48 h | induces apoptosis at the long-time exposure | 20842425 |
HeyA8 | - | Growth Inhibition Assay | - | IC50=24.3 μM | 23877012 |
HL-60 | 0-20 μM | Cell Viability Assay | 24/48 h | decreases cell viability in both dose and time dependent manner | 22407228 |
HL-60 | 10 μM | Apoptosis Asssay | 24 h | induces apoptosis | 22407228 |
HL-60 | 2.5/5/10 μM | Function Assay | 24 h | decreases Akt and p-Akt levels dose-dependently | 22407228 |
HL-60 | 2.5/5/10 μM | Function Assay | 24 h | induces the phosphorylation of JNK1/2 in a dose dependent manner | 22407228 |
HL-60 | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
HL-60 | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
HT-29 | 5 μM | Cytotoxicity Assay | 48 h | enhances paclitaxel induced ovarian cancer cell death | 21775054 |
K1 | 0.1-3 μM | Growth Inhibition Assay | 5 d | inhibits cell growth in a dose dependent manner | 22090271 |
K562 | 20 μM | Function Assay | 48 h | induces autophagy | 22407228 |
Kasumi-1 | 0-20 μM | Cell Viability Assay | 24/48 h | decreases cell viability in both dose and time dependent manner | 22407228 |
Kasumi-1 | 10 μM | Apoptosis Asssay | 24 h | induces apoptosis | 22407228 |
Kasumi-1 | 2.5/5/10 μM | Function Assay | 24 h | decreases Akt and p-Akt levels dose-dependently | 22407228 |
Kasumi-1 | 2.5/5/10 μM | Function Assay | 24 h | induces the phosphorylation of JNK1/2 in a dose dependent manner | 22407228 |
KOC7C | 1-30 μM | Cell Viability Assay | 72 h | decreases cell viability in a dose dependent manner | 25519148 |
M41 | - | Growth Inhibition Assay | - | IC50=24.7 μM | 23877012 |
M41R | - | Growth Inhibition Assay | - | IC50=19.8 μM | 23877012 |
MAVER | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
MAVER | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
MCAS | - | Growth Inhibition Assay | - | IC50=12.5 μM | 23877012 |
MDA-MB-231 | 0-10 μM | Growth Inhibition Assay | 48 h | EC50=1.13 ± 0.07 μM | 25293576 |
MGC803 | 0.75/10 μM | Function Assay | 48 h | decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels | 23912246 |
MIA | 0-25 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 24519751 |
MIA | 0.5 μM | Function Assay | 24 h | inhibits Akt, S6K1, and Erk1/2 phosphorylation | 24519751 |
MOLM | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
MOLM | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
NCI-H727 | 0-100 μM | Cell Viability Assay | 24/72 h | decreases cell viability in both dose and time dependent manner | 22499437 |
OAW-42 | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~10 μM, inhibits cell growth in a dose dependent manner | 20405296 |
OCI | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
OCI | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
OCUT1 | 0.1-3 μM | Growth Inhibition Assay | 5 d | inhibits cell growth in a dose dependent manner | 22090271 |
OCUT1 | 3 μm | Function Assay | 24 h | causes a dramatic increase in G2/M phase | 22090271 |
OVCAR5 | - | Growth Inhibition Assay | - | IC50=6.7 μM | 23877012 |
OVCAR8 | - | Growth Inhibition Assay | - | IC50=31.1 μM | 23877012 |
OVISE | 1-30 μM | Cell Viability Assay | 48 h | decreases cell viability in a dose dependent manner | 25519148 |
PA-1 | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~25 μM, inhibits cell growth in a dose dependent manner | 20405296 |
PANC-1 | 0-25 μM | Growth Inhibition Assay | 72 h | inhibits cell growth in a dose dependent manner | 24519751 |
PANC-1 | 0.5 μM | Function Assay | 24 h | inhibits Akt, S6K1, and Erk1/2 phosphorylation | 24519751 |
RMG1 | 1-30 μM | Cell Viability Assay | 72 h | decreases cell viability in a dose dependent manner | 25519148 |
RMG1 | 30 μM | Apoptosis Asssay | 24 h | induces apoptosis | 25519148 |
RMG2 | 1-30 μM | Cell Viability Assay | 72 h | decreases cell viability in a dose dependent manner | 25519148 |
RMG2 | 1-30 μM | Cell Viability Assay | 48 h | decreases cell viability in a dose dependent manner | 25519148 |
RMG2 | 30 μM | Apoptosis Asssay | 24 h | induces apoptosis | 25519148 |
SGC7901 | 0.75/10 μM | Function Assay | 48 h | decreases p-Akt (Ser 473), p-GSK3β (Ser 9), and C-MYC levels | 23912246 |
SKOV3 | 1-30 μM | Cell Viability Assay | 48 h | decreases cell viability in a dose dependent manner | 25519148 |
SKOV3 | 5 μM | Cytotoxicity Assay | 48 h | enhances paclitaxel induced ovarian cancer cell death | 21775054 |
SKOV3 | 0-40 μM | Growth Inhibition Assay | 72 h | IC50~30 μM, inhibits cell growth in a dose dependent manner | 20405296 |
SKW6.4 | 2-10 μM | Growth Inhibition Assay | 48 h | inhibits cell growth in a dose dependent manner | 20130960 |
SKW6.4 | 10 μM | Apoptosis Asssay | 24/48 h | induces apoptosis time-dependently | 20130960 |
T24 BC | 0.5/1/2.5 μM | Function Assay | 3 h | reduces the basal CB tyrosine phosphorylation levels in a dose-dependent manner | 26097873 |
T24 BC | 0.5/1/2.5 μM | Cell Viability Assay | 24 h | enhances sorafenib-induced cell viability decrease | 26097873 |
T24 BC | 2.5 μM | Apoptosis Asssay | 24 h | sensitizes BC cells to sorafenib-induced apoptotic | 26097873 |
TykNu | - | Growth Inhibition Assay | - | IC50=3.5 μM | 23877012 |
TykNuR | - | Growth Inhibition Assay | - | IC50=5.5 μM | 23877012 |
U-87 MG | 20 μM | Function Assay | 24 h | increases double-membrane bound structures | 25934232 |
U-87 MG | 20 μM | Function Assay | 6/24 h | increases the levels of LC3-II cotreated with CQ | 25934232 |
U-87 MG | 20 μM | Function Assay | 6/24 h | increases the autophagic flux at 6 h while inhibits this flux at 24h | 25934232 |
U-87 MG | 20/40 μM | Growth Inhibition Assay | 24/48 h | inhibits cell growth in both time and dose dependent manner | 25934232 |
U87MG | 0-25 μM | Cell Viability Assay | 24-96 h | decreases cell viability in both dose and time dependent manner | 24065522 |
UL-1 | 0.1–100 μM | Growth Inhibition Assay | 48 h | IC50=7.01 μM | 24881508 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01555281 | Multiple Myeloma | Phase 1 Phase 2 | Active, not recruiting | December 2019 | Italy ... more >> Istituto Europeo di Oncologia IEO Milano, Italy, 20141 University of Torino Torino, Italy, 10127 Switzerland Kantonsspital Aarau Aarau, Switzerland, 5001 Kantonsspital Baden Baden, Switzerland, 5404 Istituto Oncologico Svizzera Italiana IOSI Bellinzona, Switzerland, 6500 Inselspital Bern Bern, Switzerland, 3010 Kantonsspital Graubünden Chur, Switzerland, 7000 Kantonsspital Olten Olten, Switzerland, 4600 Kantonsspital St. Gallen St. Gallen, Switzerland, 9007 Regionalspital Thun, Switzerland, 3600 UniversitätsSpital Zürich Zürich, Switzerland, 8091 Collapse << |
NCT00055380 | Cancer | Phase 1 | Completed | - | United States, Maryland ... more >> National Institute of Dental And Craniofacial Research (NIDCR) Bethesda, Maryland, United States, 20892 Collapse << |
NCT00053794 | Endometrial Cancer ... more >> Sarcoma Collapse << | Phase 2 | Completed | - | Canada, Alberta ... more >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, British Columbia British Columbia Cancer Agency - Vancouver Island Cancer Centre Vancouver, British Columbia, Canada, V5Z 4E6 Canada, Ontario Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Mount Sinai Hospital - Toronto Toronto, Ontario, Canada, M5G 1X5 Canada, Quebec Maisonneuve-Rosemont Hospital Montreal, Quebec, Canada, H1T 2M4 Collapse << |
NCT00053781 | Melanoma (Skin) | Phase 2 | Completed | - | Canada, Alberta ... more >> Tom Baker Cancer Center - Calgary Calgary, Alberta, Canada, T2N 4N2 Canada, Nova Scotia Nova Scotia Cancer Centre Halifax, Nova Scotia, Canada, B3H 1V7 Canada, Ontario Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital at University Health Network Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Centre Hospitalier de l'Universite de Montreal Montreal, Quebec, Canada, H2L-4M1 McGill University Montreal, Quebec, Canada, H2W 1S6 Collapse << |
NCT00019656 | Leukemia Lymp... more >>homa Myelodysplastic Syndromes Myelodysplastic/Myeloproliferative Neoplasms Unspecified Adult Solid Tumor, Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 NCI - Center for Cancer Research Bethesda, Maryland, United States, 20892 Collapse << |
NCT00054145 | Breast Cancer | Phase 2 | Completed | - | Canada, Ontario ... more >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Ottawa Regional Cancer Centre Ottawa, Ontario, Canada, K1H 1C4 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00060437 | Prostate Cancer | Phase 2 | Completed | - | United States, Maryland ... more >> Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support Bethesda, Maryland, United States, 20892-1182 Collapse << |
NCT00005794 | Unspecified Adult Solid Tumor,... more >> Protocol Specific Collapse << | Phase 1 | Completed | - | United States, Wisconsin ... more >> University of Wisconsin Comprehensive Cancer Center Madison, Wisconsin, United States, 53792-6164 Collapse << |
NCT00053924 | Pancreatic Cancer | Phase 2 | Completed | - | Canada, Ontario ... more >> Margaret and Charles Juravinski Cancer Centre Hamilton, Ontario, Canada, L8V 5C2 Cancer Care Ontario-London Regional Cancer Centre London, Ontario, Canada, N6A 4L6 Princess Margaret Hospital Toronto, Ontario, Canada, M5G 2M9 Collapse << |
NCT00064324 | Recurrent Adult Soft Tissue Sa... more >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma Collapse << | Phase 2 | Completed | - | United States, Minnesota ... more >> Mayo Clinic Rochester, Minnesota, United States, 55905 Collapse << |
NCT00431054 | Ovarian Cancer | Phase 1 | Completed | - | United States, Texas ... more >> UT MD Anderson Cancer Center Houston, Texas, United States, 77030 Collapse << |
NCT01097018 | Colorectal Cancer | Phase 3 | Completed | - | - |
NCT00399126 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... more >> AOI Pharmaceuticals Investigative Site Johnson City, Tennessee, United States, 37604 Collapse << |
NCT00399087 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... more >> Investigative Site Johnson City, Tennessee, United States, 37604 Collapse << |
NCT00062387 | Head and Neck Cancer | Phase 2 | Terminated(Administratively co... more >>mplete.) Collapse << | - | United States, Illinois ... more >> University of Chicago Cancer Research Center Chicago, Illinois, United States, 60637-1470 Decatur Memorial Hospital Cancer Care Institute Decatur, Illinois, United States, 62526 Evanston Northwestern Health Care - Evanston Hospital Evanston, Illinois, United States, 60201-1781 Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 LaGrange Memorial Hospital LaGrange, Illinois, United States, 60525 Cardinal Bernardin Cancer Center at Loyola University Medical Center Maywood, Illinois, United States, 60153 Oncology/Hematology Associates of Central Illinois, P.C. Peoria, Illinois, United States, 61602 Central Illinois Hematology Oncology Center Springfield, Illinois, United States, 62701 United States, Indiana Fort Wayne Medical Oncology and Hematology, Incorporated Fort Wayne, Indiana, United States, 46885-5099 CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Michigan Oncology Care Associates, P.L.L.C. Saint Joseph, Michigan, United States, 49085 United States, Wisconsin Medical College of Wisconsin Cancer Center Milwaukee, Wisconsin, United States, 53226 Collapse << |
NCT00301938 | Accelerated Phase Chronic Myel... more >>ogenous Leukemia Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Acute Promyelocytic Leukemia (M3) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Blastic Phase Chronic Myelogenous Leukemia Myelodysplastic/Myeloproliferative Neoplasms Previously Treated Myelodysplastic Syndromes Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia T-cell Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Collapse << | Phase 1 | Completed | - | United States, Maryland ... more >> University of Maryland Greenebaum Cancer Center Baltimore, Maryland, United States, 21201-1595 Collapse << |
NCT00415064 | Multiple Myeloma | Phase 1 | Completed | - | United States, Michigan ... more >> Ann Arbor, Michigan, United States, 48109 Collapse << |
NCT00398697 | Neoplasms | Phase 1 | Completed | - | United States, Tennessee ... more >> Johnson City, Tennessee, United States, 37604 Collapse << |
NCT02238496 | Brain Tumor, Recurrent ... more >> Glioblastoma Anaplastic Astrocytoma Anaplastic Oligodendroglioma Mixed Glioma Collapse << | Phase 2 | Unknown | December 2016 | United States, New York ... more >> Columbia University Medical Center New York City, New York, United States, 10032 Memorial Sloan-Kettering Cancer Center New York City, New York, United States, 10065 Collapse << |
NCT00059982 | Pancreatic Cancer | Phase 2 | Completed | - | United States, Illinois ... more >> CCOP - Carle Cancer Center Urbana, Illinois, United States, 61801 United States, Indiana CCOP - Northern Indiana CR Consortium South Bend, Indiana, United States, 46601 United States, Iowa CCOP - Iowa Oncology Research Association Des Moines, Iowa, United States, 50309-1016 United States, Massachusetts Tufts - New England Medical Center Boston, Massachusetts, United States, 02111 United States, Minnesota CCOP - Duluth Duluth, Minnesota, United States, 55805 Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 CCOP - Metro-Minnesota Saint Louis Park, Minnesota, United States, 55416 United States, New York MBCCOP-Our Lady of Mercy Cancer Center Bronx, New York, United States, 10466 United States, North Dakota CCOP - Merit Care Hospital Fargo, North Dakota, United States, 58122 United States, Texas CCOP - Scott and White Hospital Temple, Texas, United States, 76508 Collapse << |
NCT00399152 | Renal Cancer ... more >>GIST Collapse << | Phase 1 | Completed | - | - |
NCT00398814 | Renal Cancer ... more >>Tumors Collapse << | Phase 1 | Completed | - | - |
NCT00058214 | Adenocarcinoma of the Prostate... more >> Recurrent Prostate Cancer Stage IIB Prostate Cancer Stage III Prostate Cancer Stage IV Prostate Cancer Collapse << | Phase 2 | Terminated(Did not meet interi... more >>m stopping criteria for continuation to the second stage.) Collapse << | - | United States, California ... more >> UC Davis Cancer Center Sacramento, California, United States, 95817 Collapse << |
NCT00401388 | Chondrosarcomas ... more >> Alveolar Soft Part Sarcomas Extra Skeletal Myxoid Chondrosarcomas Collapse << | Phase 2 | Completed | - | - |
NCT00422656 | Waldenstrom's Macroglobulinemi... more >>a Collapse << | Phase 2 | Completed | - | United States, Massachusetts ... more >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00422656 | - | - | Completed | - | - |
NCT01051557 | - | - | Terminated | - | - |
NCT00399789 | Non Small Cell Lung Cancer | Phase 1 Phase 2 | Completed | - | United States, Arizona ... more >> AOI Pharmaceuticals Investigative Site Tucson, Arizona, United States, 85704 United States, California AOI Pharmaceuticals Investigative Site Pomona, California, United States, 91767 United States, Florida AOI Pharmaceuticals Investigative Site Aventura, Florida, United States, 33180 AOI Pharmaceuticals Investigative Site Hollywood, Florida, United States, 33021 AOI Pharmaceuticals Investigative Site Lakeland, Florida, United States, 33805 AOI Pharmaceuticals Investigative Site Ormond Beach, Florida, United States, 32174 United States, Georgia AOI Pharmaceuticals Investigative Site Lawrenceville, Georgia, United States, 30045 United States, Illinois AOI Pharmaceuticals Investigative Site Galesburg, Illinois, United States, 61401 United States, Indiana AOI Pharmaceuticals Investigative Site New Albany, Indiana, United States, 47150 United States, Michigan AOI Pharmaceuticals Investigative Site Grand Rapids, Michigan, United States, 49546 AOI Pharmaceuticals Investigative Site Kalamazoo, Michigan, United States, 49048 United States, Montana AOI Pharmaceuticals Investigative Site Billings, Montana, United States, 59101 United States, New Mexico AOI Pharmaceuticals Investigative Site Albuquerque, New Mexico, United States, 87109 United States, New York AOI Pharmaceuticals Investigative Site Albany, New York, United States, 12208 AOI Pharmaceuticals Investigative Site Armonk, New York, United States, 10504 United States, South Carolina AOI Pharmaceuticals Investigative Site Greenville, South Carolina, United States, 29605 United States, Tennessee AOI Pharmaceuticals Investigative Site Chattanooga, Tennessee, United States, 37404 AOI Pharmaceuticals Investigative Site Nashville, Tennessee, United States, 37203 United States, Texas AOI Pharmaceuticals Investigative Site Dallas, Texas, United States, 75237 AOI Pharmaceuticals Investigative Site Dallas, Texas, United States, 75246 AOI Pharmaceuticals Investigative Site Tyler, Texas, United States, 75702 Collapse << |
NCT01051557 | Adult Anaplastic Astrocytoma ... more >> Adult Anaplastic Oligodendroglioma Adult Diffuse Astrocytoma Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma Adult Mixed Glioma Adult Oligodendroglioma Recurrent Adult Brain Neoplasm Collapse << | Phase 1 Phase 2 | Terminated | - | United States, New Jersey ... more >> Memorial Sloan Kettering Basking Ridge Basking Ridge, New Jersey, United States, 07920 United States, New York Memorial Sloan Kettering Commack Commack, New York, United States, 11725 Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT00058214 | - | - | Terminated(Did not meet interi... more >>m stopping criteria for continuation to the second stage.) Collapse << | - | - |
NCT00401011 | Multiple Myeloma ... more >> Multiple Myeloma in Relapse Collapse << | Phase 1 Phase 2 | Completed | - | - |
NCT00391560 | Leukemia | Phase 2 | Completed | - | - |
NCT00398879 | Colon Cancer | Phase 2 | Completed | - | - |
NCT00398710 | Waldenström's Macroglobulinemi... more >>a Collapse << | Phase 2 | Completed | - | United States, Massachusetts ... more >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Collapse << |
NCT00776867 | Solid Tumors | Phase 1 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT00498966 | Kidney Cancer | Phase 2 | Completed | - | United States, Kentucky ... more >> Investigative Site Louisville, Kentucky, United States, 40202 United States, New Jersey Investigative Site Morristown, New Jersey, United States, 07962 United States, New York Investigative Site Armonk, New York, United States, 10504 Collapse << |
NCT00847366 | Non Small Cell Lung Cancer ... more >> Solid Tumors Metastatic Breast Cancer Sarcomas Collapse << | Not Applicable | Completed | - | - |
NCT01002248 | Multiple Myeloma | Phase 3 | Terminated | - | - |
NCT00455559 | Gastrointestinal Stromal Tumor... more >>s Collapse << | Phase 2 | Completed | - | - |
NCT00448721 | Renal Cell Carcinoma | Phase 2 | Completed | - | United States, California ... more >> Investigative Site Duarte, California, United States, 91010 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02115 United States, Pennsylvania Investigative Site Philadelphia, Pennsylvania, United States, 19104 United States, Tennessee Investigative Site Nashville, Tennessee, United States, 37232 Collapse << |
NCT00375791 | Multiple Myeloma | Phase 2 | Completed | - | United States, California ... more >> Investigative Site Berkeley, California, United States, 94704 Investigative Site Duarte, California, United States, 91010 United States, Georgia Investigative Site Atlanta, Georgia, United States, 30322 United States, Illinois Investigative Site Chicago, Illinois, United States, 60611 United States, Massachusetts Investigative Site Boston, Massachusetts, United States, 02115 United States, Michigan Investigative Site Ann Arbor, Michigan, United States, 48103 United States, Virginia Investigative Site Charlottesville, Virginia, United States, 22908 Collapse << |
NCT00873457 | Chronic Lymphocytic Leukemia ... more >> Small Lymphocytic Lymphoma Collapse << | Phase 2 | Completed | - | United States, North Carolina ... more >> Duke University Medical Center Durham, North Carolina, United States, 27710 Collapse << |
NCT00389077 | Tumors Lympho... more >>mas Collapse << | Phase 2 | Completed | - | - |
NCT00873457 | - | - | Completed | - | - |
NCT01224730 | Cancer | Phase 1 | Completed | - | United States, Texas ... more >> Dallas, Texas, United States, 75230 Houston, Texas, United States, 77030 Collapse << |
NCT01048580 | Colon Cancer | Phase 1 | Completed | - | - |
NCT00590954 | Malignant Gliomas ... more >> CNS Brain Cancer Cancer Collapse << | Phase 2 | Active, not recruiting | May 2019 | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
NCT01049841 | Pediatric Solid Tumors | Phase 1 | Completed | - | United States, New York ... more >> Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 Collapse << |
靶点 | Description | IC50 |
---|---|---|
Akt | IC50:4.7μM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网